Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

astrazeneca uk limited - terbutaline sulfate - solution for inhalation - 5mg/2 millilitre

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

astrazeneca uk limited - terbutaline sulfate - tablets - 7.5 milligram

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

profind wholesale ltd - terbutaline sulfate - powder for inhalation - 500 mcg/acutuation

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

mcdowell pharmaceuticals - terbutaline sulfate - powder for inhalation - 500 mcg/dose

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - terbutaline sulfate - powder for inhalation - 500 mcg/dose

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

ltt pharma limited - terbutaline sulfate - powder for inhalation - 500 mcg/acutuation

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

ips healthcare limited - terbutaline sulfate - powder for inhalation - 500 microgram

Malesia - Kiingereza - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pharmaniaga manufacturing berhad - terbutaline sulphate -

Kenya - Kiingereza - Pharmacy and Poisons Board

adcock ingram ltd. p.o. box 101674-00101 nairobi - terbutaline sulphate 1.25mg ammonium chloride… - oral suspension - terbutaline sulphate 1.25mg ammonium chloride… - adrenergics for systemic use: selective

Marekani - Kiingereza - NLM (National Library of Medicine)

baxter healthcare corporation - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate in 5% dextrose injection is indicated for: magnesium sulfate in 5% dextrose injection is contraindicated in patients: risk summary magnesium sulfate in 5% dextrose injection is indicated in pregnant women for the prevention of eclampsia in women with preeclampsia and the treatment of seizures and prevention of recurrent seizures in women with eclampsia. fetal, neonatal, and maternal risks are discussed throughout the labeling. clinical considerations labor or delivery: magnesium sulfate in 5% dextrose injection is not approved for the treatment of pre-term labor. administration of magnesium sulfate in 5% dextrose injection to pregnant women longer than 5 to 7 days may lead to hypocalcemia and bone abnormalities in the developing fetus, including skeletal demineralization and osteopenia [see warnings and precautions (5.1)] . the use of intravenous magnesium in pregnant women increases human milk magnesium concentrations only slightly and oral absorption of magnesium by the infant